$KRON
Kronos Bio, Inc.

2021 Q1 Form 10-Q Financial Statement

#000174183021000028 Filed on May 11, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.590M $1.410M
YoY Change 580.14%
% of Gross Profit
Research & Development $17.59M $6.195M
YoY Change 184.0%
% of Gross Profit
Depreciation & Amortization $400.0K $200.0K
YoY Change 100.0%
% of Gross Profit
Operating Expenses $26.18M $7.349M
YoY Change 256.21%
Operating Profit -$26.18M -$7.349M
YoY Change 256.21%
Interest Expense $0.00 $1.000K
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $92.00K $354.0K
YoY Change -74.01%
Pretax Income -$26.09M -$7.000M
YoY Change 272.71%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$26.09M -$6.995M
YoY Change 272.92% 123.48%
Net Earnings / Revenue
Basic Earnings Per Share -$0.48
Diluted Earnings Per Share -$0.48 -$0.13
COMMON SHARES
Basic Shares Outstanding 54.15M shares
Diluted Shares Outstanding 54.15M shares

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $398.9M
YoY Change
Cash & Equivalents $141.4M $28.80M
Short-Term Investments $257.5M
Other Short-Term Assets $5.100M
YoY Change
Inventory
Prepaid Expenses
Receivables $1.300M
Other Receivables $0.00
Total Short-Term Assets $405.3M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $38.90M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $41.70M
YoY Change
Other Assets $114.0K
YoY Change
Total Long-Term Assets $82.69M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $405.3M
Total Long-Term Assets $82.69M
Total Assets $488.0M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.586M
YoY Change
Accrued Expenses $4.275M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $11.29M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $2.025M
YoY Change
Total Long-Term Liabilities $2.025M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $11.29M
Total Long-Term Liabilities $2.025M
Total Liabilities $42.70M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$138.0M
YoY Change
Common Stock $54.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $445.3M -$29.83M
YoY Change
Total Liabilities & Shareholders Equity $488.0M
YoY Change

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$26.09M -$6.995M
YoY Change 272.92% 123.48%
Depreciation, Depletion And Amortization $400.0K $200.0K
YoY Change 100.0%
Cash From Operating Activities -$19.00M -$7.066M
YoY Change 168.86%
INVESTING ACTIVITIES
Capital Expenditures $1.505M $626.0K
YoY Change 140.42%
Acquisitions
YoY Change
Other Investing Activities -$86.64M $5.940M
YoY Change -1558.59%
Cash From Investing Activities -$88.15M $5.310M
YoY Change -1760.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $590.0K $20.00K
YoY Change 2850.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $585.0K $12.00K
YoY Change 4775.0%
NET CHANGE
Cash From Operating Activities -$19.00M -$7.066M
Cash From Investing Activities -$88.15M $5.310M
Cash From Financing Activities $585.0K $12.00K
Net Change In Cash -$106.6M -$1.744M
YoY Change 6010.21%
FREE CASH FLOW
Cash From Operating Activities -$19.00M -$7.066M
Capital Expenditures $1.505M $626.0K
Free Cash Flow -$20.50M -$7.692M
YoY Change 166.55%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001741830
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity File Number
EntityFileNumber
001-39592
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
Kronos Bio, Inc.
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-1895605
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1300 So. El Camino Real
CY2021Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
San Mateo
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94402
CY2021Q1 dei City Area Code
CityAreaCode
650
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
781-5200
CY2021Q1 dei Security12b Title
Security12bTitle
Common stock, $0.001 par value per share
CY2021Q1 dei Trading Symbol
TradingSymbol
KRON
CY2021Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
56069854 shares
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
141448000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
248009000 USD
CY2021Q1 us-gaap Short Term Investments
ShortTermInvestments
257476000 USD
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
165052000 USD
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6347000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6741000 USD
CY2021Q1 us-gaap Assets Current
AssetsCurrent
405271000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
419802000 USD
CY2021Q1 us-gaap Long Term Investments
LongTermInvestments
41684000 USD
CY2020Q4 us-gaap Long Term Investments
LongTermInvestments
49001000 USD
CY2021Q1 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
14021000 USD
CY2020Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
13646000 USD
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
24845000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
27322000 USD
CY2021Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2026000 USD
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2027000 USD
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
114000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
166000 USD
CY2021Q1 us-gaap Assets
Assets
487961000 USD
CY2020Q4 us-gaap Assets
Assets
511964000 USD
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3586000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4550000 USD
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4275000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4974000 USD
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
822000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
937000 USD
CY2021Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2602000 USD
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2395000 USD
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
11285000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12856000 USD
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
29394000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
31120000 USD
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2025000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2469000 USD
CY2021Q1 us-gaap Liabilities
Liabilities
42704000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
46445000 USD
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54385963 shares
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54385963 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54073901 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54073901 shares
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
54000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
54000 USD
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
583218000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
577390000 USD
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-137992000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-111906000 USD
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-23000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-19000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
445257000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
465519000 USD
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
487961000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
511964000 USD
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17594000 USD
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6195000 USD
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8584000 USD
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1154000 USD
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
26178000 USD
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
7349000 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-26178000 USD
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7349000 USD
CY2021Q1 us-gaap Interest Expense
InterestExpense
0 USD
CY2020Q1 us-gaap Interest Expense
InterestExpense
1000 USD
CY2021Q1 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
92000 USD
CY2020Q1 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
355000 USD
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
92000 USD
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
354000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-26086000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-6995000 USD
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4000 USD
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
158000 USD
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6837000 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26090000 USD
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.48
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.23
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
54152656 shares
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5694832 shares
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2020Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
465519000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
590000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5238000 USD
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-26086000 USD
CY2021Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2021Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
445257000 USD
CY2019Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
21504893 shares
CY2019Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
122907000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-23203000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
20000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
188000 USD
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
158000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-6995000 USD
CY2020Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
21504893 shares
CY2020Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
122907000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-29832000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-26086000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-6995000 USD
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
444000 USD
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
160000 USD
CY2021Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-943000 USD
CY2020Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-17000 USD
CY2021Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-16000 USD
CY2020Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
68000 USD
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5238000 USD
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
188000 USD
CY2021Q1 kron Lease Expense Noncash
LeaseExpenseNoncash
461000 USD
CY2020Q1 kron Lease Expense Noncash
LeaseExpenseNoncash
68000 USD
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-971000 USD
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
150000 USD
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-52000 USD
CY2020Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1199000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-244000 USD
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
228000 USD
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-286000 USD
CY2021Q1 kron Increase Decrease In Right Of Use Operating Assets And Liabilities Net
IncreaseDecreaseInRightOfUseOperatingAssetsAndLiabilitiesNet
-175000 USD
CY2020Q1 kron Increase Decrease In Right Of Use Operating Assets And Liabilities Net
IncreaseDecreaseInRightOfUseOperatingAssetsAndLiabilitiesNet
-271000 USD
CY2021Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-241000 USD
CY2020Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-27000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18998000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7066000 USD
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1505000 USD
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
626000 USD
CY2021Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
126060000 USD
CY2020Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
2309000 USD
CY2021Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
39416000 USD
CY2020Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
8245000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-88149000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5310000 USD
CY2021Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
5000 USD
CY2020Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
8000 USD
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
590000 USD
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
20000 USD
us-gaap Net Income Loss
NetIncomeLoss
-138000000.0 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
585000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-106562000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1744000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
250036000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32570000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
143474000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30826000 USD
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
588000 USD
CY2020Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
686000 USD
CY2021Q1 kron Right Of Use Asset Increase Decrease Due To Modification
RightOfUseAssetIncreaseDecreaseDueToModification
-1741000 USD
CY2020Q1 kron Right Of Use Asset Increase Decrease Due To Modification
RightOfUseAssetIncreaseDecreaseDueToModification
0 USD
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
141448000 USD
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28800000 USD
CY2021Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2026000 USD
CY2020Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2026000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
143474000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30826000 USD
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. </span></div>Significant estimates and assumptions reflected in these condensed financial statements include, but are not limited to, the accrual of research and development expenses, the fair value of convertible notes and investments, income tax uncertainties, the valuation of equity instruments and the incremental borrowing rate for determining the operating lease assets and liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company’s estimates.The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including expenses, clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets.
CY2021Q1 kron Cash And Cash Equivalent And Debt Securities Available For Sale Amortized Cost
CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost
435334000 USD
CY2021Q1 kron Cash And Cash Equivalent And Debt Securities Available For Sale Gross Unrealized Gain Before Tax
CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax
27000 USD
CY2021Q1 kron Cash And Cash Equivalent And Debt Securities Available For Sale Gross Unrealized Loss Before Tax
CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax
50000 USD
CY2021Q1 kron Cash And Cash Equivalent And Debt Securities Available For Sale
CashAndCashEquivalentAndDebtSecuritiesAvailableForSale
435311000 USD
CY2020Q4 kron Cash And Cash Equivalent And Debt Securities Available For Sale Amortized Cost
CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost
450890000 USD
CY2020Q4 kron Cash And Cash Equivalent And Debt Securities Available For Sale Gross Unrealized Gain Before Tax
CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax
18000 USD
CY2020Q4 kron Cash And Cash Equivalent And Debt Securities Available For Sale Gross Unrealized Loss Before Tax
CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax
37000 USD
CY2020Q4 kron Cash And Cash Equivalent And Debt Securities Available For Sale
CashAndCashEquivalentAndDebtSecuritiesAvailableForSale
450871000 USD
CY2021Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
136151000 USD
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
236818000 USD
CY2021Q1 us-gaap Short Term Investments
ShortTermInvestments
257476000 USD
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
165052000 USD
CY2021Q1 us-gaap Long Term Investments
LongTermInvestments
41684000 USD
CY2020Q4 us-gaap Long Term Investments
LongTermInvestments
49001000 USD
CY2021Q1 us-gaap Investments And Cash
InvestmentsAndCash
435311000 USD
CY2020Q4 us-gaap Investments And Cash
InvestmentsAndCash
450871000 USD
CY2021Q1 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
268574000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
287686000 USD
CY2021Q1 us-gaap Available For Sale Securities Debt Maturities Rolling Year Two Through Five Fair Value
AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue
41684000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Rolling Year Two Through Five Fair Value
AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue
49001000 USD
CY2021Q1 us-gaap Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue
125053000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue
114184000 USD
CY2021Q1 us-gaap Investments And Cash
InvestmentsAndCash
435311000 USD
CY2020Q4 us-gaap Investments And Cash
InvestmentsAndCash
450871000 USD
CY2020Q1 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0 USD
CY2021Q1 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0 USD
CY2021Q1 kron Debt Securities Available For Sale Accrued Interest
DebtSecuritiesAvailableForSaleAccruedInterest
1274000 USD
CY2020Q4 kron Debt Securities Available For Sale Accrued Interest
DebtSecuritiesAvailableForSaleAccruedInterest
612000 USD
CY2021Q1 kron Prepaid Equipment Service Contracts
PrepaidEquipmentServiceContracts
343000 USD
CY2020Q4 kron Prepaid Equipment Service Contracts
PrepaidEquipmentServiceContracts
383000 USD
CY2021Q1 kron Prepaid External Research And Development And Outside Services
PrepaidExternalResearchAndDevelopmentAndOutsideServices
1287000 USD
CY2020Q4 kron Prepaid External Research And Development And Outside Services
PrepaidExternalResearchAndDevelopmentAndOutsideServices
1889000 USD
CY2021Q1 kron Prepaid Software
PrepaidSoftware
742000 USD
CY2020Q4 kron Prepaid Software
PrepaidSoftware
736000 USD
CY2021Q1 us-gaap Prepaid Insurance
PrepaidInsurance
1958000 USD
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
2881000 USD
CY2021Q1 us-gaap Prepaid Rent
PrepaidRent
743000 USD
CY2020Q4 us-gaap Prepaid Rent
PrepaidRent
240000 USD
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6347000 USD
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
200000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6741000 USD
CY2021Q1 us-gaap Finance Lease Right Of Use Asset Before Accumulated Amortization
FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
0 USD
CY2020Q4 us-gaap Finance Lease Right Of Use Asset Before Accumulated Amortization
FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
139000 USD
CY2021Q1 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
15747000 USD
CY2020Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
14931000 USD
CY2021Q1 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
1726000 USD
CY2020Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
1285000 USD
CY2021Q1 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
14021000 USD
CY2020Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
13646000 USD
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
400000 USD
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
841000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2274000 USD
CY2021Q1 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
4000 USD
CY2020Q4 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
558000 USD
CY2021Q1 kron Accrued External Research And Development Current
AccruedExternalResearchAndDevelopmentCurrent
2530000 USD
CY2020Q4 kron Accrued External Research And Development Current
AccruedExternalResearchAndDevelopmentCurrent
1017000 USD
CY2021Q1 kron Accrued Outside Services Current
AccruedOutsideServicesCurrent
714000 USD
CY2020Q4 kron Accrued Outside Services Current
AccruedOutsideServicesCurrent
0 USD
CY2021Q1 kron Accrued Leasehold Improvements Current
AccruedLeaseholdImprovementsCurrent
0 USD
CY2020Q4 kron Accrued Leasehold Improvements Current
AccruedLeaseholdImprovementsCurrent
927000 USD
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
186000 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
198000 USD
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4275000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4974000 USD
CY2021Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
0 USD
CY2020Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
5000 USD
CY2021Q1 us-gaap Deferred Compensation Share Based Arrangements Liability Current
DeferredCompensationShareBasedArrangementsLiabilityCurrent
2063000 USD
CY2020Q4 us-gaap Deferred Compensation Share Based Arrangements Liability Current
DeferredCompensationShareBasedArrangementsLiabilityCurrent
2174000 USD
CY2021Q1 kron Espp Withholdings Liability Current
ESPPWithholdingsLiabilityCurrent
539000 USD
CY2020Q4 kron Espp Withholdings Liability Current
ESPPWithholdingsLiabilityCurrent
216000 USD
CY2021Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2602000 USD
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2395000 USD
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6251159 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.95
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
49900000 USD
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
785287 shares
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
29.38
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
285160 shares
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.07
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6751286 shares
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.62
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y1M24D
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
121472000 USD
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
7600000 USD
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000 USD
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
21.11
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.59
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
3.37
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
0.33
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
36300000 USD
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5238000 USD
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
188000 USD
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-26086000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-6995000 USD
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
54152656 shares
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5694832 shares
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.48
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.23
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7874010 shares
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3512721000 shares
CY2021Q1 kron Royalty Obligation Termination Period From First Commercial Sale
RoyaltyObligationTerminationPeriodFromFirstCommercialSale
P10Y
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
24845000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
27322000 USD
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
822000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
937000 USD
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
29394000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
31120000 USD
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
30216000 USD
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
32057000 USD
CY2021Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
0 USD
CY2020Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1000 USD
CY2021Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
3000 USD
CY2020Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
6000 USD
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1384000 USD
CY2020Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
419000 USD
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1200000 USD
CY2020Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
100000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
3207000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
4204000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
4330000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
4460000 USD
CY2021Q1 kron Lessee Operating Lease Liability To Be Paid Year Four And Thereafter
LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter
30624000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
46825000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
16241000 USD
CY2021Q1 us-gaap Tenant Improvements
TenantImprovements
368000 USD
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
30216000 USD

Files In Submission

Name View Source Status
0001741830-21-000028-index-headers.html Edgar Link pending
0001741830-21-000028-index.html Edgar Link pending
0001741830-21-000028.txt Edgar Link pending
0001741830-21-000028-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
image_01a.jpg Edgar Link pending
image_11a.jpg Edgar Link pending
image_21a.jpg Edgar Link pending
kron-20210331.htm Edgar Link pending
kron-20210331.xsd Edgar Link pending
kron-20210331_cal.xml Edgar Link unprocessable
kron-20210331_def.xml Edgar Link unprocessable
kron-20210331_g1.jpg Edgar Link pending
kron-20210331_htm.xml Edgar Link completed
kron-20210331_lab.xml Edgar Link unprocessable
kron-20210331_pre.xml Edgar Link unprocessable
kronq1fy2021ex101.htm Edgar Link pending
kronq1fy2021ex311.htm Edgar Link pending
kronq1fy2021ex312.htm Edgar Link pending
kronq1fy2021ex321.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending